Siglec-15 binds mucin-domain glycoproteins with extended glycans and marks an osteoclast-like, matrix remodeling myeloid state in human tumors
Glycobiology · 2026
DOI: 10.1093/glycob/cwag035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Glycobiology, 2026. Verfasst von Nohelly Derosiers und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, 3600 Civic Center Bouleva…. Hauptthemen laut MEDLINE: Osteoclasts, Polysaccharides, Myeloid Cells, Glycoproteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Department of Veteran Affairs Office of Research and Development.
Abstract (Originalsprache)
Siglec-15 has emerged as a therapeutic target in cancer, yet the glycan determinants and protein scaffolds that mediate engagement between Siglec-15-expressing myeloid cells and tumor cells remain incompletely defined. Here, we investigated the molecular basis of Siglec-15 recognition of cancer cells and examined transcriptional as well as functional programs associated with Siglec-15 expression in tumor-associated myeloid populations. Using immunoprecipitation-mass spectrometry in the pancreatic cancer cell line AsPC-1, we identified multiple mucin-domain glycoproteins enriched in Siglec-15 pulldowns. Additionally, disruption of glycan structures demonstrated that both complex N-glycans and extended mucin-type O-glycans contribute to optimal Siglec-15 binding. To define the myeloid population associated with Siglec-15 in human tumors, we interrogated publicly available single-cell RNA sequencing datasets and found that SIGLEC15 expression is enriched within a subset of tumor-associated myeloid cells exhibiting transcriptional features linked to osteoclast differentiation and extracellular matrix remodeling. Finally, in a THP-1 coculture model, Siglec-15 was further associated with DAP12-dependent tumor-induced expression of the osteoclast markers ACP5 and MMP9, together with increased release of IL-1β and IL-6. Collectively, these findings identify glycan and glycoprotein features that support Siglec-15 binding to malignant cells and associate SIGLEC15 expression with osteoclast-like and matrix remodeling myeloid programs in human cancers, providing a framework for mechanistic studies of this glyco-immune checkpoint.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, 3600 Civic Center Boulevard, 15th Floor, Philadelphia, PA 19104-6160, United States.
- Corporal Michael J. Crescenz VA Medical Center, 3900 Woodland Ave, Philadelphia, PA 19104, United States.
ORCID-Profile: Avery D Posey
Förderung
- Department of Veteran Affairs Office of Research and Development
Zitieren
APA
Derosiers, N., Aguilar, W., Lewis, H. S., MacDonald, M., & Posey, A. D. (2026). Siglec-15 binds mucin-domain glycoproteins with extended glycans and marks an osteoclast-like, matrix remodeling myeloid state in human tumors. Glycobiology. https://doi.org/10.1093/glycob/cwag035
Vancouver
Derosiers N, Aguilar W, Lewis HS, MacDonald M, Posey AD. Siglec-15 binds mucin-domain glycoproteins with extended glycans and marks an osteoclast-like, matrix remodeling myeloid state in human tumors. Glycobiology. 2026. doi:10.1093/glycob/cwag035
BibTeX
@article{Derosiers2026,
author = {Derosiers, Nohelly and Aguilar, William and Lewis, Hyeon-Gyu S and MacDonald, Morgann and Posey, Avery D},
title = {Siglec-15 binds mucin-domain glycoproteins with extended glycans and marks an osteoclast-like, matrix remodeling myeloid state in human tumors},
journal = {Glycobiology},
year = {2026},
doi = {10.1093/glycob/cwag035}
}
EUVIMED